Human TREM2 Stable Cell Line - k562

The Human TREM2 gene, located on chromosome 6p21.1, encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily. TREM2 is primarily expressed on the surface of myeloid cells such as macrophages, dendritic cells, and microglia, where it acts as a key receptor involved in immune surveillance, phagocytosis, and the regulation of inflammatory responses. The Human TREM2 Stable Cell Line - K562 is a genetically engineered cell line generated by stably transfecting the full-length human TREM2 coding sequence into the K562 background, a human chronic myelogenous leukemia cell line widely used for hematopoietic and immunological studies. These cells constitutively express TREM2 on their surface, providing a consistent and reproducible in vitro system for investigating TREM2-mediated signaling, ligand binding, and receptor function without the need for transient transfection each time.

This stable cell line serves as a valuable tool for a range of research applications. It is particularly useful in the study of neurodegenerative diseases, as TREM2 variants have been strongly linked to an increased risk of late-onset Alzheimer’s disease. Researchers can use this cell line to screen and characterize antibodies or small molecules targeting TREM2, evaluate receptor-ligand interactions, and study downstream signaling pathways such as SYK and PI3K/AKT activation. Additionally, it supports the development of immunotherapies aimed at modulating TREM2 activity in microglia and other myeloid cells. The K562-based platform also offers advantages in terms of ease of culture, high proliferation rate, and suitability for high-throughput screening, making it a practical choice for both academic laboratories and pharmaceutical drug discovery programs focused on neuroinflammation and immuno-oncology.